News

Lumos has today published its Annual Report for FY24.

Key highlights for the last year include:

• FY2024 revenue of US$11.1 million, up 6% on the previous year


• Product revenue of US$1.2 million, up 289% on the prior year, and Commercial services revenue of US$9.9 million


• Completed two transformative agreements with leading women’s health company, Hologic, for a combined total of US$14.7 million


• Received US Food and Drug Administration (FDA) clearance for FebriDx and Emergency Use Authorisation (EUA) and a CLIA Waiver (Clinical Laboratory Improvement Amendments) for ViraDx^™ point-of-care tests in the US and moved to commercialise both products


• Debt free and cash balance strengthened via successful US$5.0 million capital raise (net of costs) in equity capital and redeemed in full the Convertible Notes during the year. Cash at 30 June was US$6.5 million


• Delivered positive net operating cashflow of $US0.9 million for the year

Lumos CEO and MD, Doug Ward, commented on FY24:

"Our strong financial performance in the second half of the year is testament to the solid foundations we've laid over the past 18 months. As we move into FY2025, our priorities are clear: successfully delivering our FebriDx^® and ViraDx^™ products for the upcoming northern hemisphere flu season, advancing the FebriDx^® CLIA waiver study, and fulfilling key milestones under our Development Agreement with Hologic. We will also be actively pursuing new strategic partnerships in the point-of-care market segment.

Click here to read the Lumos' FY24 Annual Report.